Veniti's Vici Venous Stent to Be Distributed by Boston Scientific
September 11, 2017—Veniti, Inc. announced that Boston Scientific Corporation will distribute the company's Vici venous stent under a limited global distribution agreement. The terms of the agreement and specific regions and countries involved were not disclosed.
The Vici venous stent, which was launched in 2014, is designed to treat iliofemoral venous outflow obstruction. Vici is available in a conventional delivery system, as well as the Vici Verto venous stent system to provide more control in the landing of stents in areas of critical blood flow.
Veniti is currently conducting the VIRTUS trial to evaluate the safety and efficacy of the Vici venous stent for the treatment of chronic iliofemoral venous outflow obstruction under a US Food and Drug Administration investigational device exemption.
The Vici and Vici Verto devices have received CE Mark approval and are commercially available in Europe. The Vici venous stent is approved by the Australian Therapeutic Goods Administration and is commercially available in Australia. In the United States, the devices are limited to investigational use and are not approved for sale, advised Veniti.